Exact Mass: 410.14712760000003
Exact Mass Matches: 410.14712760000003
Found 91 metabolites which its exact mass value is equals to given mass value 410.14712760000003,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Linrodostat
C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent C308 - Immunotherapeutic Agent > C141144 - Immune Checkpoint Modulator C471 - Enzyme Inhibitor > C141137 - IDO1 Inhibitor D004791 - Enzyme Inhibitors C274 - Antineoplastic Agent
Lemborexant
rakanmakilactone C|rakanmakilactone D
C20H26O7S (410.13991660000005)
Cys Ser Thr Thr
C14H26N4O8S (410.14712760000003)
Cys Thr Ser Thr
C14H26N4O8S (410.14712760000003)
Cys Thr Thr Ser
C14H26N4O8S (410.14712760000003)
Asp Gly Gly Tyr
Asp Gly Tyr Gly
Asp Tyr Gly Gly
Gly Asp Gly Tyr
Gly Asp Tyr Gly
Gly Gly Asp Tyr
Gly Gly Tyr Asp
Gly Tyr Asp Gly
Gly Tyr Gly Asp
Met Ser Ser Ser
C14H26N4O8S (410.14712760000003)
Ser Cys Thr Thr
C14H26N4O8S (410.14712760000003)
Ser Met Ser Ser
C14H26N4O8S (410.14712760000003)
Ser Ser Met Ser
C14H26N4O8S (410.14712760000003)
Ser Ser Ser Met
C14H26N4O8S (410.14712760000003)
Ser Thr Cys Thr
C14H26N4O8S (410.14712760000003)
Ser Thr Thr Cys
C14H26N4O8S (410.14712760000003)
Thr Cys Ser Thr
C14H26N4O8S (410.14712760000003)
Thr Cys Thr Ser
C14H26N4O8S (410.14712760000003)
Thr Ser Cys Thr
C14H26N4O8S (410.14712760000003)
Thr Ser Thr Cys
C14H26N4O8S (410.14712760000003)
Thr Thr Cys Ser
C14H26N4O8S (410.14712760000003)
Thr Thr Ser Cys
C14H26N4O8S (410.14712760000003)
Tyr Asp Gly Gly
Tyr Gly Asp Gly
Tyr Gly Gly Asp
Darusentan
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D065128 - Endothelin Receptor Antagonists C28313 - Endothelin Receptor Antagonist Darusentan (Lu-135252) is a selective endothelin receptor A (ET-A) receptor antagonist, which binds with a Ki of 1.4 nM to the ET-A receptor and a Ki of 184 nM to ET-B receptor, respectively with a 100-fold selectivity for ETA rather than ETB receptors[1]. Darusentan competes for radiolabeled endothelin binding in rat aortic vascular smooth muscle cells (RAVSMs) membranes with single-site kinetics, exhibiting a Ki of 13 nM[2].
2-[2-[4-[(4-chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]ethanol hydrochloride
lemborexant
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives C78272 - Agent Affecting Nervous System > C142786 - Orexin Receptor Antagonist D018377 - Neurotransmitter Agents > D000068796 - Orexin Receptor Antagonists N - Nervous system > N05 - Psycholeptics > N05C - Hypnotics and sedatives
Solabegron
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists Solabegron (GW 427353) is a selective β3-adrenergic receptor agonist, stimulating cAMP accumulation in Chinese hamster ovary cells expressing the human β3-AR, with an EC50 value of 22 nM[1]. Solabegron (GW 427353) is being developed for the treatment of overactive bladder and irritable bowel syndrome[1].
6-(2,5-dimethoxyphenyl)-3-(3-propan-2-yloxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
C21H22N4O3S (410.14125420000005)
3-(4-fluorophenyl)-4,4,6,8-tetramethyl-5,6-dihydro-4H,4H-spiro[pyrrolo[3,2,1-ij]quinoline-1,2-[1,3]thiazolidine]-2,4-dione
N-[4-(1H-benzimidazol-2-yl)phenyl]-3-(2,5-dioxo-1-pyrrolidinyl)benzamide
C24H18N4O3 (410.13788379999994)
1-(4-methylbenzenesulfonyl)-4-(5-phenyl-1H-pyrazole-3-carbonyl)piperazine
C21H22N4O3S (410.14125420000005)
(2S)-2-[12-ethyl-2-hydroxy-8-(hydroxymethyl)-9-oxo-11H-indolizino[1,2-b]quinolin-7-yl]-2-hydroxybutanoic acid
N-{2-[(2E)-2-(3,4-dimethoxybenzylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazol-5-yl}acetamide
C21H22N4O3S (410.14125420000005)
N-benzyl-N-[(2-indol-2-ylidene-3H-1,3,4-thiadiazol-5-yl)methyl]-1-phenylmethanamine
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C19H26N2O6S (410.15114960000005)
2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C19H26N2O6S (410.15114960000005)
2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C19H26N2O6S (410.15114960000005)
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C19H26N2O6S (410.15114960000005)
2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C19H26N2O6S (410.15114960000005)
2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C19H26N2O6S (410.15114960000005)
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C19H26N2O6S (410.15114960000005)
(4S,7R)-4-[(3-chlorophenyl)methyl]-7-phenyl-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
7-[(4-Chlorophenyl)methyl]-4-phenyl-9-oxa-1,6,13,14-tetrazabicyclo[9.3.0]tetradeca-11,13-dien-5-one
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C19H26N2O6S (410.15114960000005)
(4R,7S)-4-[(4-chlorophenyl)methyl]-7-phenyl-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
7-[(3-Chlorophenyl)methyl]-4-phenyl-9-oxa-1,6,13,14-tetrazabicyclo[9.3.0]tetradeca-11,13-dien-5-one
SN-38 carboxylic acid
A 2-hydroxy monocarboxylic acid resulting from the hydrolysis of the delta-lactone ring of SN-38. It is a metabolite of SN-38.
MMV009085
MMV009085 is a potent PfHT1 (Plasmodium?falciparum?hexose transporter)-specific inhibitor and a potential anti-malarial agent . MMV009085 is also a human glucose transporter inhibitor, it has high potency in inhibiting both glucose uptake (IC50: 2.6 μM in glucose uptake assay) and growth of the parasites (EC50: 1.23±0.04 μM against 3D7)[1].